Corvus Pharmaceuticals CRVS
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–
CRVS Stock News
Headlines matching Corvus Pharmaceuticals or the CRVS ticker, most recent first.
- Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30
- H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27
- Corvus Pharmaceuticals (CRVS.US) will release its earnings report after market close on August 6.
- Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33
- A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40
- Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40
- Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40
- Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $33 Positive
- Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28
- H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27
- Corvus Pharmaceuticals (CRVS.US) will release its financial report after market hours on November 5.
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Cuts Target Price to $27 Negative
- Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $30 Positive
- Jefferies Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $42 Positive
No comments yet — be the first to weigh in on CRVS.
Sign in to join the discussion.